A Regulatory System Designed to Fail
The recent recalls involving contaminated moringa leaf powder should alarm every company that manufactures, imports, or sells dietary supplements in the United States. They highlight a reality that consumers rarely understand, and policymakers routinely ignore. Dietary supplements are governed by a regulatory framework intentionally designed to limit the FDA’s authority.
This is not an accidental gap, a bureaucratic oversight, or a failure of enforcement. It is the direct result of a legislative model – the Dietary Supplement Health and Education Act of 1994 (DSHEA) – that was crafted to keep FDA at arm’s length from one of the most rapidly expanding consumer health markets in the world.
A System Built for Vitamins, Not Global Supply Chains
When DSHEA passed, the supplement market was dominated by vitamins, minerals, omega-3 capsules, and protein powders. Congress never envisioned:
-
- global botanical supply chains
-
- imported raw powders from multiple continents
-
- proprietary blends with 20+ components
-
- contract manufacturers supplying dozens of brands
-
- Amazon marketplaces filled with micro-label sellers
-
- stimulant-containing “pre-workouts”
-
- nootropic stacks, or
-
- “supergreens” mixes pulling 10+ botanicals from multiple countries
Yet this is the modern market. And DSHEA has not been meaningfully updated to match it.
Under current law, FDA cannot require pre-market safety testing, vet or approve ingredients before they are sold, demand upstream supplier transparency, or impose lot-level traceability.
In addition, the agency must treat supplements as presumed safe until proven unsafe, and it often learns about a product only after someone becomes ill. Like what happened in the recent organic moringa recall.
This structure would be unthinkable for medical devices, pharmaceuticals, or food additives. But it is the everyday operating reality for supplements.
Outbreaks Reveal the Structural Weaknesses
The moringa powder outbreak and recalls illustrate how fast a single contaminated batch can spread through the system.
A lot contaminated overseas was imported by one company, blended by another, packaged into multiple branded products, sold under private-label lines, distributed by major retailers, and consumed by families nationwide.
Yet under DSHEA and FSMA’s food provisions, the importer was only required to notify its direct customers – not the contract manufacturers, not the retailers, and certainly not the end consumer. Each firm down the chain is responsible for deciding whether to act.
That is why we saw a recall only for Africa Imports’ 1kg boxes, a separate recall later from Sam’s Club, and uncertainty about whether other brands will announce recalls at all.
This fragmentation is legal. But it is not protective.
FDA Has Been Warning Congress for Years
Across multiple administrations, FDA leadership has publicly acknowledged that the agency lacks the authority it needs, DSHEA does not support preventive safety, and the supplement market has outgrown the law.
As a result, regulatory oversight remains reactive, not proactive, and supply chains are opaque. All while product contamination risks are increasing.
But Congress has not acted.
The result is a $60+ billion industry operating under a 30-year-old law written before e-commerce, globalization, or complex botanical imports became the norm.
When the Consumer Becomes the Final Test Point, the System Is Broken
The most troubling signal in the moringa outbreak is that the contamination was not discovered by the foreign supplier, the importer, the contract manufacturer, the brand owner, or the retailer.
It was discovered by a state health laboratory testing an open container from a sick consumer’s home.
That is not what “preventive controls” are supposed to look like. That is not what “risk-based oversight” means. That is not what public health protection should rely on.
Our Position: DSHEA Reform Is Not Optional – It Is Urgent
To protect consumers and bring supplements into alignment with modern food and device regulations, Congress must act. The next generation of supplement policy must include:
-
- Pre-market safety review for new ingredients
-
- Mandatory ingredient and supplier transparency
-
- Lot-level traceability for high-risk botanicals
-
- Stronger Foreign Supplier Verification requirements
-
- Mandatory finished-product testing for high-risk categories
-
- Registration and oversight of contract manufacturers, and
-
- Modernized enforcement tools and recall authority
Without meaningful modernization, outbreaks like the current one will continue; and each will reveal the same pattern: a global supply chain moving faster than the regulatory system designed to oversee it.
This is not a partisan issue. It is a public health issue. And the U.S. cannot regulate the supplement industry with a rulebook written in 1994.
Conclusion
From FDA’s perspective, the moringa recall is a compliance exercise. From MDP’s perspective, it is a warning shot.
A system that only discovers contamination after someone gets sick is not a safety system – it is a postmortem. The dietary supplement industry, FDA, and Congress must confront the reality that DSHEA’s limitations are now a liability to public health, consumer trust, and the stability of the entire supply chain.
MDP stands ready to assist companies that want to move beyond the legal minimum and adopt true risk-based controls that match the complexity of today’s global supplement marketplace.